secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kalaris Therapeutics, Inc. (KLRS)
CIK:        0001754068
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0001193125-23-004128
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AlloVir plans Phase 3 posoleucel enrollment completion in 2023; $234M cash
--------------------------------------------------------------------------

- Cash balance $234M as of Dec 31, 2022; FY 2023 operating expenses guided $150M-$170M.
- Enrollment completion for all three posoleucel Phase 3 trials expected by end of 2023; data readouts in 2024.
- Topline results from Phase 2 BKV treatment study in kidney transplant patients expected in Q1 2023.
- Final Phase 2 multi-virus prevention data presented at ASH 2022 showed substantially lower infection rates.
- CEO Diana Brainard to present at J.P. Morgan Healthcare Conference on Jan 10, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1754068/000119312523004128/0001193125-23-004128-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1754068/000119312523004128/d422387d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-004128

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer